Wegener's granulomatosis: is biologic therapy useful

UMMS Affiliation

Department of Medicine, Division of Rheumatology



Document Type


Medical Subject Headings

Animals; *Biological Therapy; Controlled Clinical Trials as Topic; Disease Models, Animal; Granulomatosis with Polyangiitis; Humans; Immunologic Factors


Musculoskeletal Diseases | Rheumatology | Skin and Connective Tissue Diseases


Wegener's granulomatosis (WG) is a complex autoimmune disorder that has been transformed from a uniformly lethal process to a chronic disease with a relapsing-remitting course. In the setting of frequent relapses, the need to manage cumulative disease damage and drug toxicities has spurred the identification and development of new potent and directed therapies. Biologic agents, which offer the potential for remission-induction and drug-sparing approaches to treat WG, have been studied in several small, open-label clinical series and one large, randomized, placebo-controlled clinical trial. This article discusses the results of these trials and the potential of these biologic agents to treat WG.

Rights and Permissions

Citation: Curr Rheumatol Rep. 2006 Aug;8(4):303-11. 10.1007/s11926-006-0014-6 Link to article on publisher's site


At the time of publication, Jonathan Kay was not yet affiliated with the University of Massachusetts Medical School.

Related Resources

Link to Article in PubMed

PubMed ID